Amphoteric liposomes comprising neutral lipids
AssigneeMarina Biotech, Inc.
InventorsSteffen Panzner, Silke Lutz, Evgenios Siepi, Claudia Muller, Ute Vinzens
Life of this patent
Estimating the term…
Abstract
An amphoteric liposome comprising neutral lipids wherein said neutral lipids are selected from the group comprising cholesterol or mixtures of cholesterol and at least one neutral or zwitterionic lipid and wherein K (neutral) of said mixtures is 0.3 or less. Said amphoteric liposome may encapsulate an active agent, such as nucleic acid therapeutics. Also disclosed are pharmaceutical compositions comprising said amphoteric liposomes as a carrier for the delivery or targeted delivery of active agents or ingredients.
Claims29
An amphoteric lipid, which lipid has an isoelectric point between 4.5 and 8.5, according to the general formula (I):
- (I) Amphoteric substance —Y—spacer—amphiphilic substance characterized in that
- (a) the amphoteric substance has at least one portion of cationic charge with a pKa value between 4 and 8 and/or at least one portion of anionic charge with a pKa value between 3 and 7 and optionally additional charge carriers,
- aa) said portion of cationic charge being selected from the group comprising imidazole, morpholine, piperazine, purine, pyridine and/or pyrimidine or derivatives thereof,
- bb) said portion of anionic charge being a carboxyl group which comprises acetic acid, bromoacetic acid, chloroacetic acid, acetoacetic acid, propionic acid, acrylic acid, butyric acid, crotonic acid, or carboxylic acids bound in the aliphatic chain;
- which comprises dicarboxylic acids that are mono-esterified or amidated or bound in the aliphatic chain;
- which comprises oligocarboxylic acids that are mono-esterified or amidated or bound in the aliphatic chain,
- (b) the spacer is a lower alkyl residue with up to 8 C atoms, with linear, branched or cyclic structure, with 0, 1 or 2 ethylenically unsaturated bonds, and 0-4 hydroxyl groups,
- (c) Y comprises —(C═O)—O—;
- —(C═O)—NH—, —NH—(C═O)—O—;
- —O—;
- —NH—;
- —CH═N—;
- —O—(O═C)—;
- —S—;
- —(O═C)—;
- —NH—(O═C)—;
- —O—(O═C)—NH—;
- —N═CH— and/or —S—S—,
- (d) the amphiphilic substance is a structure according to the general formula (II) or (III) or (IV):
- (II)
- wherein
- R1 and R2 independently are C8-C30 alkyl or acyl chains with 0, 1 or 2 ethylenically unsaturated bonds, and
- X is selected from the group comprising —O—(C═O)—;
- —NH—(C═O)—;
- —S—(C═O)—;
- —O—;
- —NH—;
- —S—;
- —N═CH—;
- —(O═C)—O—;
- —S—(O═C)—;
- —NH—(O═C)—;
- —N═CH—;
- and/or —S—S—;
- or
- wherein
- R1 and R2 independently are C8-C30 acyl chains with 0, 1 or 2 ethylenically unsaturated bonds, and
- X is —O—;
- or
- wherein
- R1 and R2 independently are C8-C30 alkyl chains with 0, 1 or 2 ethylenically unsaturated bonds, and
- X is absent or selected from the group consisting of —(C═O)—O—;
- —(C═O)—NH—;
- —(C═O)—S—;
- —NH—;
- —CH═N—;
- and/or —S—(O═C)—;
- (e) the amphiphilic substance is a 1,4- or 1,5-dicarboxylic acid such as aspartic acid, glutamic acid, malic acid, tartaric acid, citric acid, aconitic acid, citraconic acid and/or maleic acid esterified with linear C8-C30 alcohols, and/or
- (f) the amphiphilic substance is a 1,4- or 1,5-diamine of 3-aminoalanine, diaminobutyric acid, ornithine, or lysine amidated with linear C8-C30 fatty acids;
- and liposomes thereof.
An amphoteric lipid, which lipid has the structure
- wherein the long-chain amphiphilic substances independently comprise lauryl, myristyl, palmityl, stearyl, oleyl or linoleyl residues;
- and liposomes thereof.
An amphoteric lipid, which lipid has the structure
- wherein the long-chain amphiphilic substances independently comprise lauroyl, myristoyl, palmitoyl, stearoyl, oleoyl or linoleoyl residues;
- and liposomes thereof.
(canceled)
25-28. (canceled)
An in vivo transfection system, characterized in that said system comprises liposomes loaded with genetic material, said liposomes including amphoteric lipids according to formula
- (I) Amphoteric substance—Y—spacer—amphiphilic substance
- wherein
- (a) the amphoteric substance has at least one portion of cationic charge with a pKa value between 4 and 8 and/or at least one portion of anionic charge with a pKa value between 3 and 7 and optionally additional charge carriers,
- aa) said portion of cationic charge being selected from the group comprising imidazole, morpholine, piperazine, purine, pyridine and/or pyrimidine or derivatives thereof,
- bb) said portion of anionic charge being a carboxyl group which comprises acetic acid, bromoacetic acid, chloroacetic acid, acetoacetic acid, propionic acid, acrylic acid, butyric acid, crotonic acid, or carboxylic acids bound in the aliphatic chain;
- which comprises dicarboxylic acids such as oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, malic acid, tartaric acid, glutaric acid, adipic acid, caprylic acid, pimelic acid, suberic acid, cyclohexanedicarboxylic acid or cyclopentanedicarboxylic acid, mono-esterified or amidated or bound in the aliphatic chain;
- which comprises oligocarboxylic acids such as citric acid, isocitric acid or ethylenediaminetetraacetic acid, mono-esterified or amidated or bound in the aliphatic chain,
- (b) the spacer is a lower alkyl residue with up to 8 C atoms, with linear, branched or cyclic structure, with 0, 1 or 2 ethylenically unsaturated bonds, and 0-4 hydroxyl groups,
- (c) Y comprises —(C═O)—O—;
- —(C═O)—NH—, —NH—(C═O)—O—;
- —O—;
- —NH—;
- —CH═N—;
- —O—(O═C)—;
- —S—;
- —(O═C)—;
- —NH—(O═C)—;
- —O—(O═C)—NH—;
- —N═CH— and/or —S—S—,
- (d) the amphiphilic substance is a structure according to general formula (V):
- wherein
- R1 and R2 independently are C8-C30 alkyl with 0, 1 or 2 ethylenically unsaturated bonds, and
- X is selected from the group of —O—;
- —NH—;
- —S—.
32-34. (canceled)
Dependencies are inferred from the claim text.